Giant Cell

Franz DN, et al. Everolimus for subependymal giant-cell astrocytomas (SEGAs) in tuberous sclerosis (TS). ❋ Unknown (2010)

Thomas D et al. "Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study" ❋ Unknown (2010)

About 80% of patients with primary giant-cell tumors have disease that's amenable to resection, the researchers noted in the journal. ❋ Unknown (2010)

Explain to interested patients that this study proposes a systemic treatment for giant-cell tumor of bone, a rare condition, using a drug being developed to treat osteoporosis. ❋ Unknown (2010)

In a small, single-arm, open-label study, 86% of patients with giant-cell tumor of bone had a response to denosumab, a fully human monoclonal antibody, according to David Thomas, MBBS, ❋ Unknown (2010)

The presence of an elevated erythrocyte sedimentation rate, an elevated C-reactive protein level, and an elevated platelet count in the right clinical setting would also have strongly suggested giant-cell arteritis. ❋ Unknown (2009)

She had had polymyalgia rheumatica, giant-cell arteritis, and rheumatoid arthritis for many years, treated with prednisone. ❋ Unknown (2009)